[18F]FMISO PET/CT 缺氧显像作为肺纤维化临床前模型疾病进展与疗效的无创生物标志物:与[18F]FDG PET/CT 的比较
在博来霉素诱导的 C57/BL6 小鼠肺纤维化模型中,[18F]FMISO 与[18F]FDG PET/CT 均显示纤维化期肺摄取增高,且[18F]FMISO 早期摄取区域在 CT 上仍正常但后续发展为纤维化病灶;吡非尼酮和尼达尼布快速降低两种示踪剂肺摄取;早期[18F]FMISO 摄取与侵袭性进展及尼达尼布更好疗效相关。
要点
- 早期[18F]FMISO 摄取区域在 CT 正常时已预示后续纤维化病灶。
- 吡非尼酮和尼达尼布快速降低[18F]FMISO 与[18F]FDG 肺摄取。
- 早期[18F]FMISO 肺摄取与疾病侵袭性进展及尼达尼布疗效相关。
核心结论
- [18F]FMISO PET 显像是早期检测和监测肺纤维化进展及疗效的有前景工具。
研究设计与样本
- 8 周龄 C57/BL6 小鼠气管内给予博来霉素(D0)诱导肺纤维化。
- 小鼠从 D9 至 D23 每日灌胃吡非尼酮(300 mg/kg)或尼达尼布(60 mg/kg)。
- 在基线、D8/D9、D15/D16、D22/D23 进行[18F]FDG 和[18F]FMISO PET/CT 系列显像。
- D23 进行肺组织 HIF-1α 和 GLUT-1 表达的组织学检测。
主要发现
- 在已建立的肺纤维化中,CT 平均肺密度以及[18F]FDG 和[18F]FMISO 摄取均上调(分别增加 1.4 倍、2.6 倍和 3.2 倍)。
- 早期阶段,[18F]FMISO 摄取肺区域在 CT 上仍表现正常,且对应后期将恶化为纤维化病变的区域。
- 尼达尼布和吡非尼酮显著且快速降低 CT 平均肺密度以及[18F]FDG 和[18F]FMISO 肺摄取(吡非尼酮:分别降低 1.2 倍、2.9 倍和 2.6 倍;尼达尼布:分别降低 1.2 倍、2.3 倍和 2.5 倍)。
- 早期[18F]FMISO 肺摄取与侵袭性疾病进展及更好的尼达尼布疗效相关。
临床怎么用
- [18F]FMISO PET/CT 有望用于肺纤维化的早期检测、进展监测和疗效评估。
- 早期[18F]FMISO 摄取可能帮助识别侵袭性进展患者及预测尼达尼布疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor outcome and limited therapeutic options. Imaging of IPF is limited to high-resolution computed tomography (HRCT) which is often not sufficient for a definite diagnosis and has a limited impact on therapeutic decision and patient management. Hypoxia of the lung is a significant feature of IPF but its role on disease progression remains elusive. Thus, the aim of our study was to evaluate hypoxia imaging with [18F]FMISO as a predictive biomarker of disease progression and therapy efficacy in preclinical models of lung fibrosis in comparison with [18F]FDG. METHODS: Eight-week-old C57/BL6 mice received an intratracheal administration of bleomycin (BLM) at day (D) 0 to initiate lung fibrosis. Mice received pirfenidone (300 mg/kg) or nintedanib (60 mg/kg) by daily gavage from D9 to D23. Mice underwent successive PET/CT imaging at several stages of the disease (baseline, D8/D9, D15/D16, D22/D23) with [18F]FDG and [18F]FMISO. Histological determination of the lung expression of HIF-1α and GLUT-1 was performed at D23. RESULTS: We demonstrate that mean lung density on CT as well as [18F]FDG and [18F]FMISO uptakes are upregulated in established lung fibrosis (1.4-, 2.6- and 3.2-fold increase respectively). At early stages, lung areas with [18F]FMISO uptake are still appearing normal on CT scans and correspond to areas which will deteriorate towards fibrotic lesions at later timepoints. Nintedanib and pirfenidone dramatically and rapidly decreased mean lung density on CT as well as [18F]FDG and [18F]FMISO lung uptakes (pirfenidone: 1.2-, 2.9- and 2.6-fold decrease; nintedanib: 1.2-, 2.3- and 2.5-fold decrease respectively). Early [18F]FMISO lung uptake was correlated with aggressive disease progression and better nintedanib efficacy. CONCLUSION: [18F]FMISO PET imaging is a promising tool to early detect and monitor lung fibrosis progression and therapy efficacy.
引用
- Tanguy J, Goirand F, Bouchard A, et al. [18F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [18F]FDG PET/CT approach. Eur J Nucl Med Mol Imaging. 2021. PMID: 33580818. doi:10.1007/s00259-021-05209-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。